Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review

Purpose Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes. Methods Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i. Results 29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 +/- 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 +/- 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 +/- 1.1 and 7.0 +/- 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 +/- 68 ng/mL and the mean GH level (SD) was 0.7 +/- 0.5 mu g/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i. Conclusions The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.

Automated summary

This study presented new data on the use of SGLT2i in acromegalic patients with diabetes, showing positive outcomes in improving glycemic control without adverse reactions.